Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis

PLoS One. 2013 Aug 16;8(8):e71039. doi: 10.1371/journal.pone.0071039. eCollection 2013.

Abstract

Lethal mutagenesis, or virus extinction produced by enhanced mutation rates, is under investigation as an antiviral strategy that aims at counteracting the adaptive capacity of viral quasispecies, and avoiding selection of antiviral-escape mutants. To explore lethal mutagenesis of hepatitis C virus (HCV), it is important to establish whether ribavirin, the purine nucleoside analogue used in anti-HCV therapy, acts as a mutagenic agent during virus replication in cell culture. Here we report the effect of ribavirin during serial passages of HCV in human hepatoma Huh-7.5 cells, regarding viral progeny production and complexity of mutant spectra. Ribavirin produced an increase of mutant spectrum complexity and of the transition types associated with ribavirin mutagenesis, resulting in HCV extinction. Ribavirin-mediated depletion of intracellular GTP was not the major contributory factor to mutagenesis since mycophenolic acid evoked a similar decrease in GTP without an increase in mutant spectrum complexity. The intracellular concentration of the other nucleoside-triphosphates was elevated as a result of ribavirin treatment. Mycophenolic acid extinguished HCV without an intervening mutagenic activity. Ribavirin-mediated, but not mycophenolic acid-mediated, extinction of HCV occurred via a decrease of specific infectivity, a feature typical of lethal mutagenesis. We discuss some possibilities to explain disparate results on ribavirin mutagenesis of HCV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology*
  • Cell Line, Tumor
  • Guanosine Triphosphate / metabolism
  • Hepacivirus / drug effects*
  • Hepacivirus / genetics
  • Hepacivirus / growth & development
  • Hepatocytes / drug effects*
  • Hepatocytes / pathology
  • Hepatocytes / virology
  • Humans
  • Inhibitory Concentration 50
  • Mutagenesis
  • Mutagens / pharmacology*
  • Mutation Rate
  • Mycophenolic Acid / pharmacology
  • RNA, Viral / antagonists & inhibitors*
  • RNA, Viral / biosynthesis
  • Ribavirin / pharmacology*
  • Serial Passage

Substances

  • Antiviral Agents
  • Mutagens
  • RNA, Viral
  • Ribavirin
  • Guanosine Triphosphate
  • Mycophenolic Acid

Grants and funding

This work was supported by grants BFU 2011-23604, SAF2009-10403, PI 10/01505 and ref. IDI-20110115 CDTI (Centro para el Desarrollo Tecnológico Industrial) from Ministerio de Ciencia e Innovación, P09-CVI-5428 and P10-CVI-6561 from Junta de Andalucía, and Fundación Ramon Areces. CIBERehd (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) is funded at the Instituto de Salud Carlos III. A.M.O. is supported by an FPI contract from MINECO, and J.S. by a Juan de la Cierva contract from CSIC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.